Synthesis and evaluation of polycyclic pyrazolo[3,4-d]pyrimidines as PDE1 and PDE5 cGMP phosphodiesterase inhibitors

Journal of Medicinal Chemistry

Volumn 40, Issue 26, 1997, Pages 4372-4377

  Xia, Yan ^a   Chackalamannil, Samuel ^a   Czarniecki, Michael ^a   Tsai, Hsingan ^a   Vaccaro, Henry ^a   Cleven, Renee ^a   Cook, John ^a   Fawzi, Ahmad ^a   Watkins, Robert ^a   Zhang, Hongtao ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2',5' DIMETHYL 3' (PHENYLMETHYL)SPIRO[CYCLOPENTANE 1,7'(8'H)[2H]IMIDAZO[1,2 ALPHA]PYRAZOLO[4,3 E]PYRIMIDIN] 4'(5'H) ONE; ANTIHYPERTENSIVE AGENT; CYCLIC GMP; NIFEDIPINE; PHOSPHODIESTERASE INHIBITOR; UNCLASSIFIED DRUG; VERAPAMIL;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG POTENCY; DRUG SELECTIVITY; DRUG SYNTHESIS; ENZYME INHIBITION; ENZYME SYNTHESIS; NONHUMAN; ORAL DRUG ADMINISTRATION; RAT; SPONTANEOUSLY HYPERTENSIVE RAT; STRUCTURE ACTIVITY RELATION;

3',5'-CYCLIC-GMP PHOSPHODIESTERASE; 3',5'-CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; ADMINISTRATION, ORAL; ANIMALS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CYCLIC AMP; CYCLIC GMP; MAGNETIC RESONANCE SPECTROSCOPY; MOLECULAR STRUCTURE; PHOSPHODIESTERASE INHIBITORS; PHOSPHORIC DIESTER HYDROLASES; POLYCYCLIC COMPOUNDS; PYRIMIDINES; RATS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 6844260514     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm970495b     Document Type: Article

References (26)

1. Beavo, J. A. Cyclic Nucleotide Phosphodiesterases: Functional Implications of Multiple Isoforms. Physiol. Rev, 1995, 75, 725-748.
2. Sybertz, E. J.; Czarniecki, M.; Ahn, H.-S. cGMP Phosphodiesterase Inhibition: A New Mechanism for the Discovery of Therapeutic Agents. Curr. Pharm. Des. 1995, 1, 373-390.
3. (a) Czarniecki, M.; Sybertz, E. J.; Ahn, H.-S. Inhibitors of Type I and V Phosphodiesterase: Elevation of cGMP as a Therapeutic Strategy. Annu. Rep. Med. Chem. 1996, 31, 61-70.
4. (b) Sybertz, E.; Czarniecki, M. Inhibitors of PDE1 and PDE5 cGMP Phosphodiesterases: Patents and Therapeutic Potential. Exp. Opin. Ther. Patents 1997, 7, 631-639.
5. Ahn, H.-S.; Bercovici, A.; Boykow, G.; Bronnenkant, A.; Chackalamannil, S.; Chow, J.; Cleven, R.; Cook, J.; Czarniecki, M.; Domalski, C.; Fawzi, A.; Green, M.; Gündes, A.; Ho, G.; Laudicina, M.; Lindo, N.; Ma, K.; Manna, M.; McKittrick, B.; Mirzai, B.; Nechuta, T.; Neustadt, B.; Puchalski, C.; Pula, K.; Silverman, L.; Smith, E.; Stamford, A.; Tedesco, R. P.; Tsai, H.; Tulshian, D.; Vaccaro, H.; Watkins, R. W.; Weng, X.; Witkowski, J. T.; Xia, Y.; Zhang, H. Potent Tetracyclic Guanine Inhibitors of PDE1 and PDE5 cGMP Phosphodiesterases with Oral Antihypertensive Activity. J. Med. Chem. 1997, 40, 2196-2210.
6. For a general review on the synthesis and biological properties of pyrazolo[3,4-d]pyrimidines, see: Robins, R. K. The Pyrazolo[3,4-d]pyrimidines. In Heterocyclic Compounds', Elderfield, R. C., Ed.; John Wiley & Sons, Inc.: New York, 1967; Vol. 8, pp 406-421.
7. Gauri, K. K.; Erbler, H.; Eltze, M. Pyrazolo[3,4-d]pyrimidines and Pharmaceutical Compositions Containing Them. EP 63381, 1982.
8. (a) Silver, P. J.; Dundore, R. L.; Bode, D. C.; de Garavilla, L.; Buchholz, R. A.; van Aller, G.; Hamel, L. T.; Bacon, E.; Singh, B.; Lesher, G. Y.; Hlasta, D.; Pagani, E. D. Cyclic GMP Potentiation by WIN 58237, a Novel Cyclic Nucleotide Phosphodiesterase Inhibitor. J. Pharmacol. Exp. Ther. 1994, 271, 1143-1149.
9. (b) Bell, A. S.; Terrett, N. K. New Pyrazolopyrimidinones Selectively Inhibit cGMP PDE - Useful for Treating and Preventing Angina, Hypertension, Atherosclerosis etc. WO 9307149-A1, 1993.
10. (c) Bell, A. S.; Terrett, N. K. Pyrazolopyrimidinone Antianginal Agents. EP 0 526 004 A1, 1993.
11. The same reaction has been done on malononitrile: Cheng, C. C.; Robins, R. K. Potential Purine Antagonists. VI. Synthesis of 1-Alkyl- and l-Aryl-4-substituted Pyrazolo[3,4-d]pyrimidines. J. Org. Chem. 1956, 21, 1240-1256.
12. (a) Hayashi, T.; Hori, I.; Baba, H.; Midorikawa, H. Studies on Geometric Isomerism by Nuclear Magnetic Resonance. I. Stereochemistry of α-Cyano-β-alkoxy-β-alkylacrylic Esters. J. Org. Chem. 1965, 30, 695-699 and references therein.
13. (b) Avramovitch, B.; Rappoport, Z. Stereochemistry of Substitution of Good Nucleofuges at the Stereoconvergence Region as a Tool for Investigating the Rapid Step of Nucleophilic Vinylic Substitution. J. Am. Chem. Soc. 1988, 110, 911-922 and references therein,
14. (c) Hormi, O. Utilization of β-Chloro Alkylidene Malonates in Organic Synthesis: Synthesis of Ethyl Cyclopropylpropiolate. Org. Synth. 1987, 66, 173-179.
15. Schmidt, P.; Eichenberger, K.; Wilhelm, M.; Druey, J. Paraxanthin-, Theobromin- und Theophyllin-Analoga der Pyrazolo[3,4-d]pyrimidin-Reihe. Helv. Chim. Acta 1959, 42, 349-359.
16. Yoneda, F.; Nagamatsu, T.; Nagamura, T. Synthesis of Pyrazolo[3,4-d]pyrimidines by Intramolecular Cycloaddition of Azahexatrienes. J. Chem. Soc. Perkin I 1977, 765-767.
17. The (-)-trans-2-aminocyclopentanol can be prepared in > 96% ee using the method of Overman, L. E.; Sugai, S. A Convenient Method for Obtaining trans-2-Aminocyclohexanol and trans-2- Aminocyclopentanol in Enantiomerically Pure Form. J. Org. Chem. 1985, 50, 4154-4155.
18. For application of NOE in pyrazole structural determinations, see: Holzer, W. NOE Difference Spectroscopy as a Versatile Tool for Spectral and Structural Assignment in Various N-1 Substituted Pyrazoles. Tetrahedron 1991, 47, 1393-1398.
19. Thompson, W. J.; Brooker, G.; Appleman, M. M. Assay of Cyclic Nucleotide Phosphodiesterases with Radioactive Substrates. Methods Enzymol. 1974, 38, 205-212.
20. Ahn, H.-S.; Crim, W.; Romano, M.; Sybertz, E.; Pitts, B. Effects of selective Inhibitors on Cyclic Nucleotide Phosphodiesterases of Rabbit Aorta. Biochem. Pharmacol. 1989, 38, 3331-3339.
21. Sonnenburg, W. K.; Mullaney, P. J.; Beavo, J. A. Molecular Cloning of a Cyclic GMP Stimulated Cyclic Nucleotide Phosphodiesterase cDNA. J. Biol. Chem. 1991, 266, 17655-17661.
22. Harrison, S. A.; Reifsnyder, D. H.; Gallis, B.; Cadd, G. G.; Beavo, J. A. Isolation and Characterization of Bovine Cardiac Muscle cGMP Inhibited Phosphodiesterase; A Receptor for New Cardiotonic Drugs. Mol. Pharmacol. 1986, 29, 506-514.
23. Thompson, W. J.; Shen, C.-C.; Strada, S. J. Preparation of Dog Kidney High-affinity cAMP Phosphodiesterase. Methods Enzymol. 1988, 159, 760-772.
24. Thomas, M. K.; Francis, S. H.; Corbin, J. D. Characterization of a Purified Bovine Lung cGMP Binding cGMP Phosphodiesterase. J. Biol. Chem. 1990, 265, 14964-14970.
25. Smith, E. M.; Swiss, G. F.; Neustadt, B. R.; Gold, E. H.; Sommer, J. A.; Brown, A. D.; Chiu, P. J. S.; Moran, R.; Sybertz, E. J.; Baum, T. Synthesis and Pharmacological Activity of Angiotensin Converting Enzyme Inhibitors: N-(Mercaptoacyl)-4-substituted-(s)-proline. J. Med. Chem. 1988, 31, 875-885.
26. Vemulapalli, S.; Watkins, R. W.; Chintala, M.; Davis, H.; Ahn, H.-S.; Fawzi, A.; Tulshian, D.; Chiu, P.; Chatterjee, M.; Lin, C.-C.; Sybertz, E. J. Antiplatelet and Antiproliferative Effects of SCH 51866, a Novel Type 1 and Type 5 Phosphodiesterase Inhibitor. J. Cardiovasc. Pharmacol. 1996, 28, 862-869.